Drug: PF-00547659 – injection under the skin
The TURANDOT Program is a clinical research study being conducted worldwide to test the effectiveness of PF-00547659 in treating ulcerative colitis (UC). PF-00547659 is being studied because it may decrease the inflammation and ulceration of UC by decreasing the attraction of white blood cells to the intestines and preventing the wearing away of healthy tissue in the colon. If you decide to take part, you will first complete the induction phase. For this phase you will be asked to visit the study center 6 times over the 12-week study period. You will be asked to return to the site for these visits to complete a routine check-up and receive a dose of the study medicine, which will be an injection under the skin. Your visits will likely include laboratory tests (blood, urine, and stool), a weight check, and a physical examination. On some occasions, you may also need to complete forms or questionnaires. If you complete this study, you will have the option to join the open-label phase of the study, which will allow access to the drug for up to 2 years. This will involve returning to the site every 4 weeks for an injection under the skin. There is no placebo involved in this portion of the study. You will be reimbursed for time and travel for each visit completed.
I am interested in more information about this study.